06.08.26 -- April's CDMO Opportunities And Threats Report

Explore a cost-effective approach with a comprehensive AAV analytical package that holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Silencing cargo gene expression during LVV and AAV production improves cell health, reduces impurities, and significantly increases vector yield for cytotoxic and difficult‑to‑manufacture transgenes.

Discover how automation and digitalization are transforming cell and gene therapy with scalable, decentralized manufacturing and smarter market navigation.

Successful viral vector scale‑up depends on early process design, predictive models, and execution strategies that anticipate GMP realities rather than simply increasing production volume.

Listen as industry experts share their experiences, including why and how cellular source materials are cryopreserved and why experience across cell types and methods matters.

Learn about this new platform approach that streamlines lentiviral vector design and manufacturing, boosting yield, lowering costs, and accelerating access to gene‑modified cell therapies worldwide.

Effective CGT development hinges on phase-appropriate manufacturing. Matching manufacturing rigor to the clinical phase ensures the right quality at the right time while reducing costs and accelerating timelines.